Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Organization Of Cell Sheet Tissue Engineering Regenerative Medicine Initiatives is currently active in the Biotechnology & Pharmaceuticals technology area. The portfolio contains 1 pending office action, which is being handled by a distinct examiner. This indicates a highly focused prosecution effort for the organization's current filings. Because the workload is situated within a distinct art unit, the applicant only needs to address the procedural requirements of a specialized group at the patent office.
The busiest examiner for this portfolio is BOECKELMAN, JACOB A, who is responsible for 1 busiest_examiner_pending office action. Having this individual as the point of contact for the pending workload allows for a consistent and direct dialogue between the applicant and the examiner. This streamlined interaction can be beneficial, as it eliminates the need to manage conflicting feedback from multiple officials.
Practitioners should note that the concentration of the portfolio under BOECKELMAN, JACOB A in the biotechnology sector suggests a clear path for prosecution. With the pending office action workload being so centralized, the applicant can focus their resources on the specific concerns raised by this examiner. This structure avoids the complexities often found in larger portfolios that are spread across various examiners and art units.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| BOECKELMAN, JACOB A | 1 | 34.9% | +46.5% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18016491 | CHONDROCYTE CELL SHEETS AND METHODS FOR THEIR PRODUCTION AND USE | BOECKELMAN, JACOB A | — |
| Art Unit | Apps |
|---|---|
| 1655 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18016491 | CHONDROCYTE CELL SHEETS AND METHODS FOR THEIR PRODUCTION AND USE | BOECKELMAN, JACOB A | 1655 | §103 | Final Rejection | — | Pending | Jan 17, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialOrganization Of Cell Sheet Tissue Engineering Regenerative Medicine Initiatives has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Jacob A Boeckelman has the most, with 1 of Organization Of Cell Sheet Tissue Engineering Regenerative Medicine Initiatives's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
